Tablon, Elena D.

HRN: 28-68-84  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/11/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
03/11/2026
03/18/2026
IV
4.5G
Q6
ARF SEC TO CAP HR
Remove - Pending Acceptance
03/11/2026
AZITHROMYCIN 500MG TABLET (TAB)
03/11/2026
03/18/2026
PO
500MG
OD
ARF SEC TO CAP HR
Remove - Pending Acceptance
03/11/2026
AZITHROMYCIN 500MG TABLET (TAB)
03/11/2026
03/15/2026
PO
500mg
OD
ARF Sec To CAP-HR
Remove - Pending Acceptance
03/20/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/20/2026
03/27/2026
IVT
2.25g
Q8
CAP HR
Remove - Pending Acceptance
03/21/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/21/2026
03/27/2026
IV
2.25 G
Q6h
CAP-HR
Remove - Pending Acceptance
03/29/2026
MUPIROCIN 2%, 15G (TUBE)
03/29/2026
04/05/2026
TOPICAL
Apply On Affected Area
BID
Infected Bed Sore
Remove - Pending Acceptance
03/29/2026
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
03/29/2026
04/05/2026
IV
250mg
Q48hrs
VAP
Remove - Pending Acceptance
03/29/2026
CEFTAZIDIME 1GM (VIAL)
03/29/2026
04/05/2026
IV
500
Q24hrs
VAP
Remove - Pending Acceptance
03/30/2026
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
03/30/2026
04/06/2026
TOPICAL
Apply On Affected Area
BID
Decubitus Ulcer
Remove - Pending Acceptance
04/06/2026
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
04/06/2026
04/13/2026
IV
750mg
Now, Then Q 48 Hours
HAP
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: